Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03622112 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 808
- Enrollment target
NCT03622112 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 808 participants.
The verdict
NCT03622112, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 808 participants
- Enrollment target
Study Summary
This study will assess the efficacy and safety of multiple dose levels of AZD7594 administered once daily (QD) by inhalation in a 12-week treatment period on asthma subjects. The activity will be assessed by comparing AZD7594 to placebo. The comparison between active comparator (FF) and placebo will be used for bench marking. The efficacy is assessed by the evaluation of change in trough forced expiratory volume in 1 second (FEV1). The aim is to develop AZD7594 as a once daily inhaled non-steroidal selective GR modulator (SGRM), which may ultimately lead to better disease control of both chronic obstructive pulmonary disease (COPD) and asthma through improved efficacy and compliance. The overall rationale for developing a once daily AZD7594 in a dry powder inhaler (DPI) is to provide a safe and effective future treatment option for both asthma and COPD subjects.
Interventions
- DRUG AZD7594 DPI 55μg/50μg.
- DRUG AZD7594 DPI 99 µg/90 µg
- DRUG AZD7594 DPI 198 µg/180 µg
- DRUG AZD7594 DPI 396 µg/360 µg once daily.
- DRUG AZD7594 DPI 792 µg/720 µg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 808 participants |
| Start Date | 2019-01-02 |
| Est. Completion | 2019-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03622112
The ClinicalTrials.gov registry entry for NCT03622112 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 808 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which AZD7594 DPI 55μg/50μg. is the first listed.
NCT03622112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03622112 about?
NCT03622112 is a clinical study titled "A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects". This study will assess the efficacy and safety of multiple dose levels of AZD7594 administered once daily (QD) by inhalation in a 12-week treatment period on asthma subjects. The activity will be assessed by comparing AZD7594 to placebo. The comparison between active comparator (FF) and placebo will...
What is the current status of trial NCT03622112?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 808 participants. The study started on 2019-01-02. Estimated completion is 2019-09-30.
What interventions are being tested in trial NCT03622112?
The interventions under investigation include: AZD7594 DPI 55μg/50μg. (DRUG), AZD7594 DPI 99 µg/90 µg (DRUG), AZD7594 DPI 198 µg/180 µg (DRUG), AZD7594 DPI 396 µg/360 µg once daily. (DRUG), AZD7594 DPI 792 µg/720 µg (DRUG).
Who is sponsoring clinical trial NCT03622112?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.